Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolonging Adjuvant Tamoxifen Treatment in Early Breast Cancer
NCT00003678Phase 3Unknown
- Sponsor
- University Hospitals Birmingham
- Start
- May 1991
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tamoxifen in breast cancer (2 arms), sponsored by University Hospitals Birmingham. Primary endpoint: All-cause mortality. Status: unknown.
02
Drugs
tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00003678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003678.